Player FM - Internet Radio Done Right
21 subscribers
Checked 1d ago
Добавлено четыре года назад
Контент предоставлен Proactive Investors. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Proactive Investors или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Player FM - приложение для подкастов
Работайте офлайн с приложением Player FM !
Работайте офлайн с приложением Player FM !
Scancell CEO on first-half progress and 2025 milestones
Manage episode 463984748 series 2891889
Контент предоставлен Proactive Investors. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Proactive Investors или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Scancell Holdings PLC CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company’s latest interim results and its progress. He highlighted five key updates, including the latest data from the SCOPE study, which investigates the company’s cancer vaccine for melanoma. The interim results showed an 80% disease control rate and a 72% overall response rate, significantly outperforming current standard-of-care treatments. L’Huillier also discussed the strong recruitment progress in the SCOPE and ModiFY studies, as well as an additional licensing deal with Genmab, reinforcing industry validation of Scancell’s antibody portfolio. The company recently raised £11.3 million, securing funding to advance its clinical programs through 2025 and into the second half of 2026. He noted organizational changes, including his appointment as CEO and the hiring of Dr Nermeen Varawalla as chief medical officer, allowing Professor Lindy Durrant to refocus on scientific leadership as CSO. Looking ahead, Scancell expects multiple clinical data readouts in 2025, including full results from the SCIB1 arm of the SCOPE study by mid-year, as well as new data from the next-generation iSCIB1+ vaccine. Updates from the ModiFY study, including further efficacy results from the Modi-1 vaccine in head and neck cancer, are also anticipated in the second half of the year. L’Huillier expressed confidence in Scancell’s future, emphasising its strong clinical pipeline, robust team, and committed investor base. “We have the team and the resources to execute the plan, and we will do that.” For more updates on Scancell and its progress, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for more interviews. #Scancell #Biotech #CancerResearch #Immunotherapy #SCOPEStudy #ModiFYStudy #ClinicalTrials #HealthcareInnovation #Biopharma #Investing
…
continue reading
605 эпизодов
Manage episode 463984748 series 2891889
Контент предоставлен Proactive Investors. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Proactive Investors или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Scancell Holdings PLC CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company’s latest interim results and its progress. He highlighted five key updates, including the latest data from the SCOPE study, which investigates the company’s cancer vaccine for melanoma. The interim results showed an 80% disease control rate and a 72% overall response rate, significantly outperforming current standard-of-care treatments. L’Huillier also discussed the strong recruitment progress in the SCOPE and ModiFY studies, as well as an additional licensing deal with Genmab, reinforcing industry validation of Scancell’s antibody portfolio. The company recently raised £11.3 million, securing funding to advance its clinical programs through 2025 and into the second half of 2026. He noted organizational changes, including his appointment as CEO and the hiring of Dr Nermeen Varawalla as chief medical officer, allowing Professor Lindy Durrant to refocus on scientific leadership as CSO. Looking ahead, Scancell expects multiple clinical data readouts in 2025, including full results from the SCIB1 arm of the SCOPE study by mid-year, as well as new data from the next-generation iSCIB1+ vaccine. Updates from the ModiFY study, including further efficacy results from the Modi-1 vaccine in head and neck cancer, are also anticipated in the second half of the year. L’Huillier expressed confidence in Scancell’s future, emphasising its strong clinical pipeline, robust team, and committed investor base. “We have the team and the resources to execute the plan, and we will do that.” For more updates on Scancell and its progress, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for more interviews. #Scancell #Biotech #CancerResearch #Immunotherapy #SCOPEStudy #ModiFYStudy #ClinicalTrials #HealthcareInnovation #Biopharma #Investing
…
continue reading
605 эпизодов
Kaikki jaksot
×
1 Plurilock Secures contract with leading New York hospital, extends NASA cybersecurity partnership 8:43
Plurilock Securities CEO Ian L. Paterson joined Steve Darling from Proactive to announce significant milestones for the company, which provides advanced cybersecurity solutions to the United States and Canadian federal governments, as well as Global 2000 companies. The company recently secured an $800,000 USD, 11-month contract with a top 10 U.S. hospital located in New York. Through its subsidiary, Aurora Systems Consulting, Plurilock will deliver customized cybersecurity services designed to protect the hospital's critical infrastructure from escalating cyber threats. Paterson emphasized the growing demand for secure, tailored technology solutions in the healthcare sector, where sensitive data and patient safety are prime targets for cyberattacks. The contract underscores Plurilock’s commitment to helping healthcare institutions modernize their systems while ensuring robust cybersecurity measures are in place. This new deal adds to a series of recent contract wins, including three key sales through federal procurement channels such as the U.S. government’s SEWP V contract vehicle and Canadian federal procurement initiatives. Notably, Plurilock secured contracts with U.S. Cyber Command and the U.S. Navy, further expanding its footprint within critical government agencies. Additionally, Plurilock announced that NASA Headquarters has approved an extension of its existing contract, ensuring uninterrupted procurement of essential IT and cybersecurity solutions for federal agencies. The contract extension will run through October 31, 2025, with two optional three-month extensions available, potentially extending the agreement by an additional year. These recent wins demonstrate Plurilock’s continued success in securing high-value contracts across healthcare and government sectors, reinforcing its position as a trusted provider of cybersecurity solutions. #proactiveinvestors #plurilcoksecuritiesinc #tsxv #plur #otcqb #plckf Cybersecurity #IanPaterson #EnterpriseSecurity #USDefense #HealthcareCybersecurity #NASA #SEWPContract #CodeAndCountry…

1 Bravada Gold expands portfolio with East Walker acquisition, eyes partnerships for key projects 6:41
Bravada Gold CEO Joe Kizis joined Steve Darling from Proactive to share updates on the company’s ongoing exploration efforts in Nevada, focusing on its gold and silver projects: Wind Mountain, Highland, and the newly acquired East Walker property. Kizis highlighted the strong economics of the Wind Mountain project, which has the potential to produce 40,000 to 50,000 ounces of gold annually. While the company continues advancing the project, it is actively seeking a joint venture partner to help bring Wind Mountain into production. The Highland project, known for its geological similarities to Nevada’s renowned Midas deposit, has yielded “spectacular intercepts” from both surface sampling and drilling, underscoring its potential for high-grade gold mineralization. Bravada’s latest acquisition, the East Walker project, is modeled after the Silicon Merlin discovery in Nevada’s Walker Lane, a region known for its rich mineral deposits. This strategic addition further strengthens Bravada’s portfolio in one of North America’s premier mining jurisdictions. While Kizis acknowledged the current challenges in securing joint venture partnerships, he expressed optimism about the industry’s outlook, noting increased exploration activity as a positive sign. “There are people getting active. They think things are going to improve. And that's really good for our business model,” Kizis stated. With a diversified portfolio and promising exploration results, Bravada Gold remains well-positioned to capitalize on Nevada’s rich mineral potential as market conditions improve. #proactiveinvestors #bravadagoldcorporation #tsxv #bva #otcqb #bgavf GoldExploration #NevadaMining #JosephKizis #WindMountainProject #HighlandProject #EastWalker #MiningInvesting #GoldStocks #ProactiveInvestors…
GoviEx Uranium Inc head of investor relations Isabel Vilela talked with Proactive's Stephen Gunnion about the latest developments for the company, including progress on the Mutanga project in Zambia and the renewed discussions regarding the Madaouela project in Niger. Vilela shared positive news on the Madaouela project, highlighting that GoviEx had suspended arbitration against the Government of Niger after signing a letter of intent outlining a roadmap for future discussions. "The Ministry of Mines had reached out to us during Indaba... It is still early days, and there is no guarantee that we will, in fact, find an amicable solution," Vilela said. On the Mutanga project front, GoviEx has appointed Endeavor Financial as advisors to expedite financing. The project boasts a Net Present Value (NPV) of $243 million and an Internal Rate of Return (IRR) of nearly 21%, with a production target of 2.2 million pounds per year starting in 2028. Vilela emphasized Mutanga's advantages, including its simple, open-pit design and Zambia's stable mining environment. Looking ahead, GoviEx is focused on financing, finalising its Environmental and Social Impact Assessment (ESIA) by the end of this quarter, and advancing discussions with off-takers. "We are working on a number of things, and we are looking forward to developing this project," Vilela added. For more interviews and insights, visit Proactive's YouTube channel. Don't forget to like the video, subscribe, and enable notifications for future content. #GoviExUranium #UraniumMining #MutangaProject #MadaouelaProject #ZambiaMining #NigerMining #MiningInvesting #ProactiveInvestors #ESIA #EndeavorFinancial…
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s significant progress toward securing European patents for its SIRT6 variant, marking a major milestone. The patent, which mirrors an earlier US patent, covers the composition of matter for the SIRT6 gene variant, a discovery made alongside the University of Colombia, Rochester University, and the Albert Einstein School of Medicine. Leire explained that the SIRT6 variant was identified through research on a unique population of Jewish Ashkenazi centenarians, showing a mutation that boosts SIRT6 activity. Highlighting the gene's role in managing DNA damage and epigenomic changes, he noted, "We are in a safer position because we secure one of the very important competitive advantages over other longevity companies." Genflow plans to apply this SIRT6 gene variant to age-related conditions such as Non-Alcoholic Steato Hepatitis (NASH), sarcopenia, and glaucoma, utilising gene therapy tools to precisely target affected areas. Beyond human applications, Leire mentioned an upcoming dog study focused on life extension and nerve cell preservation in ageing dogs, with an announcement expected soon. As Genflow enters the national phase of patent preparation, Leire emphasised the process is largely bureaucratic with minimal risk. Stay tuned for updates as the company continues to advance its innovative longevity research. For more insightful interviews and updates, visit Proactive’s YouTube channel! Don’t forget to like, subscribe, and enable notifications for future content. #GenflowBiosciences #SIRT6 #LongevityResearch #DrEricLeire #BiotechNews #EuropeanPatent #GeneTherapy #Healthspan #AgingResearch #ProactiveInterviews…
Far East Gold Ltd (ASX:FEG) CEO Shane Menere talked with Proactive’s Tylah Tully about the company’s latest developments, including receiving the final tranche of a key investment agreement with Xingye Gold (Hong Kong) Mining Company Limited. Menere described this as a pivotal moment for Far East Gold, as the investment will support the company’s exploration and development activities. He highlighted the significance of the partnership with Xingye Gold, a strategic player in the gold mining sector, which brings both financial backing and industry expertise. Far East Gold continues to focus on advancing its portfolio of gold projects. Menere outlined plans for increased exploration efforts, particularly in high-potential regions. With strong gold prices and rising demand, the company is positioning itself for growth in 2025 and beyond. With new funding secured and strategic partnerships in place, Far East Gold aims to accelerate its drilling and resource expansion programs. Menere emphasised that this deal strengthens the company’s long-term vision and commitment to delivering shareholder value. #FarEastGold #GoldExploration #MiningNews #ASXStocks #XingyeGold #GoldMining #GoldInvesting #ResourceDevelopment #MiningUpdates #ProactiveInvestors…
Orthocell Ltd has submitted an application to the Thailand Food and Drug Administration seeking approval for the sale of its nerve repair product, Remplir™, in the US$84 million Thai market. This move is part of the company’s broader global expansion strategy, following strong sales growth in Australia, New Zealand, and Singapore. Thailand has a well-developed healthcare system and a strong medical tourism sector, making it a key market in the Asia-Pacific region. Orthocell is also evaluating opportunities in Hong Kong, Taiwan, Vietnam, Indonesia, and the Philippines. The company is awaiting regulatory clearance in the US and Canada, with US FDA 510(k) approval expected in March or April 2025. This would allow Orthocell to commercially distribute Remplir in the US, a market valued at US$1.6 billion. Approval for the US$75 million Canadian market is anticipated in the second half of the year. Orthocell aims to capture 20% of the US$3.2 billion available across its selected markets. More than 180 orthopaedic and plastic surgeons currently use Remplir in peripheral nerve repair surgeries in Australia, New Zealand, and Singapore. #Orthocell, #MedicalTechnology, #NerveRepair, #HealthcareInnovation, #RegulatoryApproval, #Remplir, #Surgery, #CollagenWrap, #MedicalDevices, #Thailand, #AsiaPacific, #MarketExpansion, #USFDA, #Canada, #Orthopaedics, #PlasticSurgery, #Healthcare, #Investment, #Growth, #Revenue…

1 Just the facts: Elixir Energy secures Mongolian farm-out agreements to fund Grandis expansion 1:44
Elixir Energy Ltd has signed two farm-out agreements for its Mongolian natural gas and renewable energy assets. The agreements transfer a 51% interest in these projects to a UK-registered company controlled by Mongolian business interests, which will cover all costs up to a final investment decision (FID) for gas or renewable development. The first farm-out agreement involves Elixir’s Mongolian coal bed methane (CBM) assets, including the Nomgon CBM production sharing contract (PSC) and related equipment and facilities. The second agreement applies to the company’s renewable energy business, covering the Solar Ilch pre-development solar farm, wind and solar monitoring equipment, and associated intellectual property. Elixir stated that these agreements will allow the company to focus on its Grandis Gas Project in Queensland, with the potential to fully exit the Mongolian projects under pre-agreed terms. The total possible payments from the agreements could reach A$56 million. Both deals include conditional put and call options, with exit valuations linked to booked reserves and installed renewable capacity. #ElixirEnergy, #NaturalGas, #RenewableEnergy, #Mongolia, #Queensland, #EnergyInvestment, #FarmOut, #GasExploration, #SolarEnergy, #WindEnergy, #CoalBedMethane, #JointVenture, #GrandisProject, #EnergyDevelopment, #InvestmentDeals, #OilAndGas, #Australia, #EnergyTransition, #BusinessNews, #GasReserves…
Lightning Minerals Ltd (ASX:L1M) CEO Alex Biggs talked with Proactive about the company’s latest drilling activities at the Esperança lithium project in Brazil. Biggs shared that drilling has commenced after six months of preparation across three tenements in Brazil’s Lithium Valley. The Esperança project has confirmed spodumene-bearing pegmatite, indicating lithium presence. The drilling program will cover 2,000 metres across 14 holes, with the flexibility to adapt as necessary. Biggs noted that the campaign is expected to take around eight weeks, with assay results anticipated within four to six weeks. He mentioned that Lightning Minerals will provide market updates as drilling progresses and may fast-track assays depending on early results. Beyond Esperança, Lightning Minerals is also focused on its Caraíbas and Canabrava projects. Biggs highlighted strong lithium values from soil sampling and reiterated the company’s commitment to further exploration in Brazil, which he described as a cost-effective and highly prospective lithium region. For more updates on Lightning Minerals and other mining insights, visit Proactive’s YouTube channel. #LightningMinerals #LithiumExploration #ASXNews #MiningNews #EsperançaProject #BrazilLithium #BatteryMetals #MiningUpdates #ProactiveInvestors #ElectricVehicles…
Power Nickel Inc CEO Terry Lynch joined Steve Darling from Proactive to announce the company’s rebranding to Power Metallic Mines Inc., effective February 21st, 2025. The company will continue to trade under the ticker symbol PNPN on the TSX Venture Exchange and PNPNF on the OTCQB. Lynch explained that the name change reflects a strategic shift as the company’s deposit has evolved from primarily nickel to a polymetallic opportunity, with potential reserves of copper, noble metals (PGEs, gold, silver), and nickel in equal parts. Additionally, the company has upsized its private placement offering by $10 million, increasing the total proceeds to $50 million. This financing, the company’s first brokered financing, is led by major institutions including BMO and Hannam UK and was upsized due to high investor demand, strengthening institutional support. Power Metallic Mines was also recognized as one of the 2024 TSX Venture 50 top performers, ranking as the top mining company and fourth overall with an impressive 365% share price appreciation in 2024. The TSX Venture 50 companies delivered an average share price appreciation of 207% and collectively hold a market capitalization of $21.7 billion, up by $16 billion year-over-year. Lynch noted that last year’s exploration confirmed the Lion Zone as a standout asset, and 2025 is expected to be a pivotal year as the company, now fully funded, plans to double its exploration programs. #proactiveinvestors #powernickelinc #tsxv #pnpn #otcqb #cmetf #nickel #mining #invest #investing #PowerMetallicMines #MiningIndustry #PolymetallicExploration #Copper #Nickel #TSXVenture #TerryLynch #ProactiveInvestors #InstitutionalInvestment #Gold #Silver #PGMs #Investing #ResourceSector #MiningNews…
West Wits Mining Ltd (ASX:WWI) chairman Michael Quinert spoke with Proactive’s Tylah Tully about securing a credit approval term sheet for a senior debt syndicated loan facility of up to ZAR 902.5 million (about US$50 million). He highlighted that this funding, backed by two of South Africa’s leading financial institutions, was a critical step forward for the company. The funds will support the Qala Shallows Gold Project, part of the larger Witwatersrand Basin Project. Quinert noted that Qala Shallows had a five-million-ounce resource, with initial production targeting one million ounces over a 17.9-year mine life. “This has been the challenge for the last 12 to 18 months — can we secure institutional-grade backing for this project? Now that we have, it gives us a strong platform to move forward,” Quinert said. With the senior debt facility secured, West Wits Mining now focuses on finalising the remaining equity funding component. Quinert remains optimistic, citing the strong gold price environment and the validation from institutional lenders as key drivers for the company’s next steps. #WestWitsMining #ASXWWI #GoldMining #MiningNews #QalaShallows #GoldStocks #Investing #Witwatersrand #Funding #ProactiveInvestors…
ACG Metals chairman and CEO Artem Volynets talked with Proactive's Stephen Gunnion about the company's strategic focus for 2025, including the construction of the sulphide expansion project at its Gediktepe mine. Volynets confirmed that the project is on track for commissioning in early 2026, setting ACG Metals on the path to becoming a copper producer with an anticipated output of up to 25,000 tonnes of copper equivalent annually. In the interview, Volynets highlighted the transformational year ACG Metals had in 2024, transitioning from a SPAC to a fully operational company through the acquisition of the Gediktepe asset. The company raised $200 million in debt to finance the expansion and restructure acquisition debt, demonstrating strong financial progress. "Now with the acquisition complete, the project fully funded, and staffed with a very experienced team, we are moving to execute on the base case scenario," Volynets said. ACG Metals achieved $75 million in EBITDA last year, and with the sulphide expansion, the base case scenario projects EBITDA to exceed $100 million. As the company shifts from gold and silver doré production to a focus on copper, it aims to see a rerating of its shares by four to five times, aligning with industry peers. For more insightful interviews and updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel, and turn on notifications for the latest content. #ACGMetals #CopperProduction #ArtemVolynets #MiningIndustry #SulphideExpansion #GediktepeAsset #GoldToCopper #ProactiveInterviews #MiningNews #EBITDAGrowth…
Ananda Pharma Plc finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the company's progress with MRX1, a promising treatment for chemotherapy-induced peripheral neuropathy (CIPN) and endometriosis pain. Ananda has completed the final GMP-certified batch needed for regulatory approval, marking a significant milestone in its clinical journey. Sturgess-Smith explained, "What we've done is we've now completed all the preparatory work before we can manufacture MRX1 to deliver to patients," emphasising the upcoming trials in Edinburgh and Australia. The trials include CIPN and endometriosis studies at Edinburgh University, as well as a phase one pharmacokinetic (PK) study in Australia. The next steps involve ethics submissions and discussions with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to ensure compliance with regulatory standards. Approval from independent ethics panels will ensure the clinical trials meet ethical standards, while stability data from these trials will support potential licensing with global regulators, including the FDA in the US and the EMA in Europe. Stay tuned to Proactive's YouTube channel for more updates on Ananda Pharma's clinical progress. Don't forget to like this video, subscribe to our channel, and enable notifications for the latest insights! #AnandaPharma #MRX1 #ClinicalTrials #CIPN #Endometriosis #PharmaNews #Biotech #MHRA #FDA #Pharmacokinetics #ProactiveInvestors…
SEEEN plc (AIM:SEEN) CEO Adrian Hargrave talked with Proactive's Stephen Gunnion about the company’s impressive growth trajectory and its focus for 2025. SEEEN, a video technology platform business, reported a revenue increase from $2.1 million in 2023 to $3.2 million in 2024, with an annualised run rate of $5 million. Hargrave highlighted the company's dual approach, blending high-margin technology solutions with consultancy services for YouTube channels and creators. The company’s AI-driven platform helps clients monetise video content by identifying engaging segments and facilitating sales through contextual calls to action. SEEEN is gaining traction in the sports, e-commerce, and education sectors, showcasing innovative tools like video commerce and targeted training solutions. In 2025, SEEEN aims to maintain its cash flow-positive status while driving sales across its core vertical markets, including sports, retail, and social media. The company also plans to enhance its training solutions, a new growth avenue developed with American Leak Detection. For more insightful interviews, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for the latest updates! #SEEENplc #AdrianHargrave #VideoCommerce #AItechnology #ContentMonetization #SportsTech #Ecommerce #EdTech #2025Growth #ProactiveInvestors…
Georgina Energy PLC (LSE:GEX) CEO Anthony Hamilton talked with Proactive's Stephen Gunnion about the company's latest progress, including the near-completion of the purchase of the Mt Winter permit in Northern Territory. Hamilton highlighted that acquiring 100% control of the project offers Georgina Energy complete autonomy over its operations, eliminating external influences. He explained, "We've ended up with 100% control, 100% control of our destiny, and the program that we want to undertake isn't subject to anybody else's influence." This transition from a joint venture to full ownership allows the company to streamline its strategic objectives, particularly regarding the EPA155 permit. Hamilton detailed the process following the share sale agreement execution, including awaiting the Aboriginal Land Rights Agreement (ALRA) and the subsequent ministerial approval. Once granted, Georgina Energy will proceed with its drilling approval application alongside a comprehensive resource revaluation. The discussion also touched on the company’s Western Australia Officer Basin operations, where severe weather, including a major cyclone, has delayed the Environmental Impact Study (EIS). Despite these challenges, Georgina Energy remains focused on maintaining its 60-day EIS completion target. Stay tuned to Proactive's YouTube channel for more insightful interviews. Don’t forget to give this video a like, subscribe to our channel, and enable notifications for future updates! #GeorginaEnergy #AnthonyHamilton #MtWinterPermit #OilAndGas #NorthernTerritory #WesternAustralia #ResourceExploration #ShareholderValue #EnergySector #ProactiveInvestors…
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the latest findings on IMU-856, a drug candidate initially studied for celiac disease. New data suggests that IMU-856 significantly increases endogenous GLP-1 levels in a dose-dependent manner, which could make it a potential oral treatment for obesity. Vitt detailed the results of a post hoc analysis from a Phase 1b clinical trial, where patients receiving the highest dose of IMU-856 experienced a 250% increase in baseline GLP-1 levels. He also discussed preclinical safety studies in rats, which demonstrated a dose-dependent reduction in weight gain—further supporting the drug's potential in obesity management. The global obesity treatment market is projected to reach $170 billion, with current solutions mainly relying on injectable GLP-1 mimetics. Vitt highlighted that IMU-856’s potential as an oral therapy could offer a new and more convenient option for patients. Stay updated on Immunic Inc’s progress by watching Proactive’s latest interviews. Don’t forget to like this video, subscribe to our channel, and enable notifications for more updates. #ImmunicInc #IMUX #Biotech #Pharmaceuticals #GLP1 #ObesityTreatment #ClinicalTrials #Healthcare #Investing #ProactiveInvestors…
Добро пожаловать в Player FM!
Player FM сканирует Интернет в поисках высококачественных подкастов, чтобы вы могли наслаждаться ими прямо сейчас. Это лучшее приложение для подкастов, которое работает на Android, iPhone и веб-странице. Зарегистрируйтесь, чтобы синхронизировать подписки на разных устройствах.